Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,500 shares, a drop of 44.4% from the March 15th total of 2,700 shares. Based on an average trading volume of 2,400 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC bought a new stake in shares of Pharming Group (NASDAQ:PHAR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,715 shares of the company’s stock, valued at approximately $134,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 14th.

Pharming Group Trading Up 4.8 %

Shares of Pharming Group stock opened at $10.48 on Thursday. Pharming Group has a 1 year low of $9.70 and a 1 year high of $16.71. The firm has a market cap of $703.31 million, a PE ratio of -74.85 and a beta of 0.16. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.06 and a quick ratio of 3.33. The company has a 50 day simple moving average of $11.27 and a two-hundred day simple moving average of $11.59.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $71.83 million. Analysts expect that Pharming Group will post -0.02 earnings per share for the current fiscal year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.